Current research on hepatitis C virus resistance to direct-acting antiviral agents
10.3969/j.issn.1001-5256.2015.11.010
- VernacularTitle:丙型肝炎相关直接抗病毒药物耐药的研究现状
- Author:
Shan REN
1
;
Xinyu CHEN
Author Information
1. Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
- Publication Type:Research Article
- Keywords:
hepacivirus;
antiviral agents;
multidrug resistance-associated proteins
- From:
Journal of Clinical Hepatology
2015;31(11):1807-1812
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, direct-acting antiviral agent(DAA) that target specific enzymes in the life cycle of hepatitis C virus (HCV) have been developed rapidly. However, there are specific resistance-related mutation sites for DAA, which is associated with the gene types/subtypes of HCV. This article describes the resistance-related mutation sites for DAA and their impacts on the treatment regimen according to the mechanism of action of DAA. It is pointed out that some natural mutation sites lead to drug resistance in the treatment for patients with some HCV subtypes, so careful evaluation is needed before treatment to determine the appropriate regimen. For patients experiencing failure in the previous interferon therapy, the pre-existing drug resistance should be studied if DAA in combination with the therapy or interferon-free DAA therapies are to be used.
